Atıf İçin Kopyala
Cadirci K., TOZLU Ö. Ö., TÜRKEZ H.
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.44, sa.5, ss.692-698, 2019 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
44
Sayı:
5
-
Basım Tarihi:
2019
-
Doi Numarası:
10.1515/tjb-2019-0111
-
Dergi Adı:
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
-
Sayfa Sayıları:
ss.692-698
-
Anahtar Kelimeler:
Dapagliflozin, MTT, LDH, Genotoxicity, Oxidant status, TYPE-2 DIABETIC-PATIENTS, GLUCOSE COTRANSPORTER 2, GLYCEMIC CONTROL, CHRONIC SAFETY, DOUBLE-BLIND, RISK, STRESS, INHIBITORS, WEIGHT
-
Atatürk Üniversitesi Adresli:
Hayır
Özet
Objectives: Dapagliflozin (DAPA), is a potent SGLT-2 inhibitor for the treatment of patients with type 2 diabetes. DAPA has a good clinical and biological tolerance profile. However little information is available on its potential effects on cultured human blood cells. The evaluation of the in vitro cytotoxicity, genotoxicity potential and antioxidant/oxidant activity of DAPA in primary human whole blood cell cultures was aimed in this study.